Dr. Scheller, who served at 23andMe for four years, has left the company to join biotechnology company BridgeBio as chairman of research and development. He will remain on 23andMe’s board of directors.
Kenneth Hillan, 23andMe’s head of therapeutics, will take over Dr. Scheller’s responsibilities but not his title, according to the report.
23andMe announced in March 2015 that it would begin to develop drugs. According to its website, the company is working on treatments for cancer and diseases that affect the skin, lungs and heart.
Read the full report here.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.